Cytokinetics ACACIA-HCM Additional Analyses Published in Circulation; MAPLE-HCM in JACC: Heart Failure Following ESC 2026 Late-Breaking Presentation
Cytokinetics (NASDAQ: CYTK) confirmed Monday August 31, 2026 the peer-reviewed publication of ACACIA-HCM additional analyses in Circulation and MAPLE-HCM in Journal of the American College of Cardiology: Heart Failure, both following the ESC Congress 2026 Late-Breaking Clinical Trial Session presentations Saturday August 29 in Munich. The ACACIA-HCM Circulation paper details cardiac structure and diastolic function improvements from aficamten (Myqorzo) in symptomatic non-obstructive hypertrophic cardiomyopathy (LV mass reduction, LV wall thickness reduction, and LA volume reduction versus placebo at Week 36), supporting the ACACIA-HCM primary readout (KCCQ Clinical Summary Score and peak VO2) that was presented Friday August 28 in the Hot Line Session and published simultaneously in the New England Journal of Medicine. The MAPLE-HCM JACC: Heart Failure paper reports the trial of aficamten versus metoprolol in obstructive HCM. Cytokinetics plans an aficamten sNDA submission in Q4 2026 for the non-obstructive HCM indication.